Brookstone Capital Management Sells 11,708 Shares of Gilead Sciences, Inc. $GILD

Brookstone Capital Management lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 103,662 shares of the biopharmaceutical company’s stock after selling 11,708 shares during the quarter. Brookstone Capital Management’s holdings in Gilead Sciences were worth $14,447,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Smith Salley Wealth Management bought a new position in Gilead Sciences during the 1st quarter worth approximately $206,000. True Vision MN LLC bought a new stake in Gilead Sciences in the first quarter valued at approximately $622,000. Evolve Private Wealth LLC increased its stake in Gilead Sciences by 8.9% in the first quarter. Evolve Private Wealth LLC now owns 27,939 shares of the biopharmaceutical company’s stock valued at $3,894,000 after purchasing an additional 2,273 shares in the last quarter. Balboa Wealth Partners raised its holdings in Gilead Sciences by 2.7% in the first quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 79 shares during the period. Finally, Montecito Bank & Trust boosted its position in shares of Gilead Sciences by 17.6% during the first quarter. Montecito Bank & Trust now owns 6,544 shares of the biopharmaceutical company’s stock worth $912,000 after purchasing an additional 980 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on GILD. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Tuesday, June 16th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Daiwa Securities Group cut their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $158.41.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 68,000 shares of company stock worth $8,930,150. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.9%

GILD opened at $124.87 on Tuesday. The stock has a market capitalization of $155.03 billion, a P/E ratio of 17.01 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The firm’s fifty day simple moving average is $131.31 and its 200 day simple moving average is $134.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.